PTPLA Inhibitors
Chemical inhibitors of PTPLA play a crucial role in modulating its function through various biochemical pathways. Trichostatin A, for instance, inhibits histone deacetylase, which can lead to altered chromatin structure and subsequently inhibit the expression of enzymes that work in conjunction with PTPLA, thereby indirectly inhibiting its function. Similarly, Manumycin A acts as a farnesyltransferase inhibitor, preventing the prenylation of proteins that are important for the localization and function of proteins interacting with PTPLA, affecting its functional role. PD 98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK pathway, which is important for the regulation of PTPLA, and its inhibition can lead to a decrease in PTPLA's activity within the cell. LY294002 and Wortmannin, as PI3K inhibitors, suppress the PI3K/AKT pathway, which is involved in metabolic regulation, an area where PTPLA is active. By disrupting this pathway, these inhibitors can lead to a decrease in PTPLA activity.
Furthermore, Rapamycin, an mTOR inhibitor, affects the mTOR signaling pathway that plays a significant role in cell growth and metabolism. As PTPLA is implicated in fatty acid synthesis, the inhibition of mTOR signaling can indirectly inhibit PTPLA activity. SB203580 and SP600125 target the p38 MAPK and JNK pathways, respectively. These pathways are integral to the cellular stress response and signaling mechanisms that regulate the cellular metabolic processes that involve PTPLA. Inhibition of these pathways leads to a functional inhibition of PTPLA. Bisindolylmaleimide I and Gö 6983, both PKC inhibitors, interrupt PKC activity, which is involved in signaling cascades that regulate metabolism and cellular processes. Inhibiting PKC can lead to an indirect inhibition of PTPLA by altering the cellular signaling that controls its function. Lastly, Cerulenin, a fatty acid synthase inhibitor, disrupts fatty acid metabolism, which is directly connected to the functional activity of PTPLA in fatty acid elongation, leading to its inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase (HDAC), which can increase acetylation of histones, leading to changes in chromatin structure and transcription. As PTPLA functions in the regulation of fatty acid elongation, alteration in chromatin structure could inhibit the expression of enzymes that work in concert with PTPLA, thus indirectly inhibiting PTPLA's functional role in the cell. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a farnesyltransferase inhibitor which can inhibit the prenylation of proteins involved in signaling pathways, including those that PTPLA may be part of. By inhibiting this modification, Manumycin A can disrupt the localization and function of proteins that interact with PTPLA, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor which prevents the activation of the MAPK/ERK pathway. PTPLA, being involved in fatty acid elongation, may rely on proper MAPK/ERK signaling for its function or regulation. Inhibition of this pathway can therefore lead to a functional inhibition of PTPLA. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which blocks the PI3K/AKT signaling pathway. This pathway is involved in numerous cellular functions including metabolism regulation where PTPLA plays a role. Inhibition of PI3K/AKT can lead to disruption of metabolic functions, indirectly inhibiting PTPLA activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, it suppresses the PI3K/AKT pathway. This inhibition can result in the disruption of cellular processes where PTPLA is involved, such as lipid metabolism, leading to a functional inhibition of PTPLA's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which can affect the mTOR signaling pathway, a crucial regulator of cell growth and metabolism. As PTPLA is involved in fatty acid synthesis, inhibition of mTOR signaling can indirectly inhibit the functional activity of PTPLA by disrupting the metabolic processes it is involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may disrupt the cellular stress response, potentially altering the regulation of enzymes involved in lipid metabolism where PTPLA functions. Thus, inhibiting p38 MAPK may lead to a functional inhibition of PTPLA. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the MAPK signaling pathways. By inhibiting JNK, SP600125 could indirectly inhibit PTPLA activity by altering the signaling mechanisms that regulate cellular metabolism processes in which PTPLA is implicated. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. PTPLA, being potentially regulated by the ERK pathway through various metabolic processes, would be functionally inhibited by the disruption of this signaling by U0126. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a protein kinase C (PKC) inhibitor. PKC is involved in various signaling cascades that regulate metabolism and cellular processes. Inhibiting PKC can indirectly inhibit PTPLA by altering the cellular signaling that controls its function within lipid metabolism. | ||||||